Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPER Study: mPFE vs mTPEx in recurrent/metastatic head and neck squamous cell carcinoma
jRCTs071180009Phase 2Completed
- Sponsor
- Merck Biopharma
- Start
- Nov 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, cisplatin, docetaxel, fluorouracil and filgrastim in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merck Biopharma. Primary endpoint: progression-free survival. Started Nov 2017; status: completed.
02
Drugs
cetuximabcisplatindocetaxelfluorouracilfilgrastim
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs071180009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180009.